Related Experiment Video
Updated: Mar 21, 2026

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement
Published on: March 26, 2018
High Risk Aortic Valve Replacement - The Challenges of Multiple Treatment Strategies with an Evolving Technology
K Booth1, R Beattie1, M McBride1
1Department of Cardiothoracic Surgery, Royal Victoria Hospital, 274 Grosvenor Road, Belfast, BT12 6BA.
For high-risk patients, surgical aortic valve replacement (SAVR) offers good outcomes when transcatheter aortic valve implantation (TAVI) is unsuitable. This study found 95.5% survival to discharge and 86% one-year survival for SAVR in such cases.
Area of Science:
- Cardiovascular Surgery
- Interventional Cardiology
- Medical Technology
Background:
- Optimal treatment for high-risk aortic valve replacement is complex.
- Transcatheter Aortic Valve Implantation (TAVI) has been an alternative since 2008.
- This study examines early TAVI and SAVR experiences in high-risk patients.
Purpose of the Study:
- To evaluate the outcomes of high-risk patients undergoing SAVR when TAVI was not feasible.
- To analyze early institutional experience with TAVI and SAVR.
- To discuss the evolving landscape of aortic valve intervention.
Main Methods:
- Database interrogation for Surgical Aortic Valve Replacement (SAVR) and TAVI referrals.
- Identification of high-risk patients who underwent SAVR due to TAVI ineligibility.
Main Results:
- Survival to hospital discharge was 95.5% for 45 patients who underwent SAVR.
- One-year survival rate for these patients was 86%.
Conclusions:
- Defining suitability for TAVI versus high-risk SAVR remains challenging.
- Multidisciplinary team discussions are crucial in this evolving field.
- TAVI introduction has increased overall aortic valve intervention offers, benefiting more patients.
More Related Videos
12:17Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Related Concept Videos
Aortic Regurgitation III: Medical Management
Mitral Stenosis III: Medical Management
Aortic Regurgitation I: Introduction
Mitral Valve Prolapse II: Assessment and Management
Aneurysm III: Interprofessional Care
Mitral Regurgitation III: Medical Management